Amgen's Sjögren's Trial Success Remains a Sideshow to Core Thesis

What happened

Amgen announced that its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease met its primary endpoint, but management acknowledged that an approval filing will await data from another ongoing trial. This indicates clinical activity but not yet a registrational package, leaving the asset years from potential revenue. Sjögren's is a niche autoimmune indication with considerably smaller commercial opportunity than Amgen's leading growth franchises such as Repatha, Tezspire, or MariTide. The news does not alter the fundamental picture of accelerating price and biosimilar erosion in legacy products, unresolved tax risk, and elevated leverage that underpins the Potential Sell rating. At ~$339 per share, the stock's premium valuation continues to hinge on obesity execution and Horizon asset growth rather than this incremental pipeline update.

Implication

Investors should treat this Sjögren's readout as a minor positive that demonstrates pipeline execution but carries no near-term financial impact; dazodalibep is unlikely to contribute meaningful revenue before 2029-2030, and its addressable market is small relative to Amgen's core products. The requirement for an additional trial before filing adds timeline risk and highlights that even successful Phase 3 data may not be sufficient for approval in this indication, tempering any enthusiasm. The market's reaction is likely muted, and those looking for catalysts should focus on Part 2 Phase 2 MariTide durability data and early Phase 3 obesity readouts that will materially affect valuation. Persistent headwinds—ENBREL net price declines of 30-38%, RANKL biosimilar erosion starting 2026, and IRA implementation—remain the dominant forces on the base business. Therefore, the strategic recommendation remains unchanged: avoid new positions at current levels and consider trimming above ~$370, while monitoring for a pullback toward ~$295 for a more attractive entry.

Thesis delta

No change to the investment thesis. The successful Sjögren's trial does not address the core risks of legacy erosion, obesity optionality, or Horizon integration that drive the Potential Sell rating. The pipeline asset adds diversification but lacks near-term commercial relevance.